Identification of the transcription factor LSF as an oncogene and the significant inhibition of tumor growth upon LSF inhibition with no observed toxicity indicate that LSF holds considerable promise as a cancer therapeutic target [2, 15, 20]. Here, TFCP2 is linked to neoplasm.